AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 277 filers reported holding AMICUS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $338,790 | +16.5% | 27,861 | +20.3% | 0.01% | +27.3% |
| Q2 2023 | $290,852 | +21.3% | 23,157 | +7.1% | 0.01% | +22.2% |
| Q1 2023 | $239,788 | -15.1% | 21,622 | 0.0% | 0.01% | -18.2% |
| Q4 2022 | $282,383 | +25.5% | 21,622 | 0.0% | 0.01% | +10.0% |
| Q3 2022 | $225,000 | +1.8% | 21,622 | +4.9% | 0.01% | 0.0% |
| Q2 2022 | $221,000 | +13.3% | 20,619 | 0.0% | 0.01% | +42.9% |
| Q1 2022 | $195,000 | -18.1% | 20,619 | 0.0% | 0.01% | -12.5% |
| Q4 2021 | $238,000 | +20.8% | 20,619 | 0.0% | 0.01% | +14.3% |
| Q3 2021 | $197,000 | -1.0% | 20,619 | 0.0% | 0.01% | 0.0% |
| Q2 2021 | $199,000 | -7.0% | 20,619 | -4.8% | 0.01% | -12.5% |
| Q1 2021 | $214,000 | -57.2% | 21,667 | 0.0% | 0.01% | -65.2% |
| Q4 2020 | $500,000 | +63.4% | 21,667 | 0.0% | 0.02% | +64.3% |
| Q3 2020 | $306,000 | -9.2% | 21,667 | -3.1% | 0.01% | -12.5% |
| Q2 2020 | $337,000 | +62.8% | 22,362 | 0.0% | 0.02% | +33.3% |
| Q1 2020 | $207,000 | -5.0% | 22,362 | 0.0% | 0.01% | +20.0% |
| Q4 2019 | $218,000 | +27.5% | 22,362 | +5.1% | 0.01% | +25.0% |
| Q3 2019 | $171,000 | -30.8% | 21,279 | +7.5% | 0.01% | -27.3% |
| Q2 2019 | $247,000 | +16.0% | 19,803 | +26.5% | 0.01% | +10.0% |
| Q1 2019 | $213,000 | +42.0% | 15,657 | 0.0% | 0.01% | +25.0% |
| Q4 2018 | $150,000 | -20.6% | 15,657 | 0.0% | 0.01% | -11.1% |
| Q3 2018 | $189,000 | -22.9% | 15,657 | 0.0% | 0.01% | -25.0% |
| Q2 2018 | $245,000 | +4.3% | 15,657 | 0.0% | 0.01% | +9.1% |
| Q1 2018 | $235,000 | +16.3% | 15,657 | +11.4% | 0.01% | +22.2% |
| Q4 2017 | $202,000 | +18.1% | 14,057 | +14.3% | 0.01% | +12.5% |
| Q3 2017 | $171,000 | +37.9% | 12,303 | 0.0% | 0.01% | +33.3% |
| Q2 2017 | $124,000 | +40.9% | 12,303 | 0.0% | 0.01% | +50.0% |
| Q1 2017 | $88,000 | +44.3% | 12,303 | 0.0% | 0.00% | +33.3% |
| Q4 2016 | $61,000 | -33.0% | 12,303 | 0.0% | 0.00% | -40.0% |
| Q3 2016 | $91,000 | – | 12,303 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |